A multicenter, randomized, double‐blind, placebo‐controlled trial of adjuvant methotrexate treatment for giant cell arteritis
2002/05/01 by Gary S. Hoffman, María C. Cid, Maria C. Cid +58 · 27 citations
Medicine · #Vasculitis and related conditions #Otitis Media and Relapsing Polychondritis #Ocular Diseases and Behçet’s Syndrome
paper · doi:10.1002/art.10262
Abstract
OBJECTIVE: To evaluate treatment with methotrexate (MTX) in patients with newly diagnosed giant cell arteritis (GCA) to determine if MTX reduces GCA relapses and cumulative corticosteroid (CS) requirements and diminishes disease- and treatment-related morbidity. METHODS: This was a multicenter, randomized, double-blind study. Over 4 years, 16 centers from the International Network for the Study of Systemic Vasculitides enrolled patients with unequivocal GCA. The initial treatment was 1 mg/kg/day (<or=60 mg every day) prednisone, plus either 0.15 mg/kg/week MTX (increased to 0.25 mg/kg/week, for a maximum weekly dosage of 15 mg) or placebo. Two physicians, both blinded to treatment allocation, evaluated each patient at every trial visit. One physician was responsible for providing global medical care. The other assessed GCA status according to a standard protocol. Treatment failure was defined as 2 distinct relapses or persistence of disease activity after the first relapse, in spite of increased CS therapy. RESULTS: Ninety-eight patients were enrolled. No significant differences between treatment groups were noted with regard to age, frequency of positive findings on temporal artery biopsy (placebo 87%, MTX 79%), or comorbidities at the time of enrollment. The median dosage of MTX was 15 mg/week. The incidence of treatment failure was comparable between groups after 12 months: 57.5% in the MTX group failed treatment (95% confidence interval [95% CI] 41.6-73.4%) compared with 77.3% in the placebo group (95% CI 61.9-92.8%) (P = 0.26). In a Cox regression analysis, MTX was not associated with a reduced risk of treatment failure (relative risk 0.72; 95% CI 0.41-1.28). There were no significant differences between groups with regard to abnormal elevations of the erythrocyte sedimentation rate following initial remissions, serious morbidity due to GCA, cumulative CS dose, or treatment toxicity. In the MTX group, there were fewer cases of GCA relapse heralded by symptoms of isolated polymyalgia rheumatica (1 case versus 5 in the placebo group; P = 0.05). CONCLUSION: The results of this randomized, multicenter trial do not support the adjunctive use of MTX to control disease activity or to decrease the cumulative dose and toxicity of CS in patients with GCA.
Cited by
- Adjunctive methotrexate for treatment of giant cell arteritis: An individual patient data meta‐analysis
- Use of immunosuppressants and biologics in giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA)
- Aortitis. [europepmc]
- The treatment of giant cell arteritis. [europepmc]
- Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda. [europepmc]
- Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis--a prospective longitudinal study. [europepmc]
- New features of disease after diagnosis in 6 forms of systemic vasculitis. [europepmc]
- Risk for cardiovascular disease early and late after a diagnosis of giant-cell arteritis: a cohort study. [europepmc]
- The value of glucocorticoid co-therapy in different rheumatic diseases--positive and adverse effects. [europepmc]
- Disease Relapses among Patients with Giant Cell Arteritis: A Prospective, Longitudinal Cohort Study. [europepmc]
- Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study. [europepmc]
- An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy. [europepmc]
- A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis. [europepmc]
- Giant cell arteritis: early diagnosis is key. [europepmc]
- Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab. [europepmc]
- PET/MRI in large-vessel vasculitis: clinical value for diagnosis and assessment of disease activity. [europepmc]
- A new era for giant cell arteritis. [europepmc]
- Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis. [europepmc]
- European Headache Federation recommendations for neurologists managing giant cell arteritis. [europepmc]
- Giant cell arteritis: Its ophthalmic manifestations. [europepmc]
- 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. [europepmc]
- 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. [europepmc]
- Efficacy and safety of secukinumab in patients with giant cell arteritis: study protocol for a randomized, parallel group, double-blind, placebo-controlled phase II trial. [europepmc]
- Large-vessel vasculitis. [europepmc]
- Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study. [europepmc]
- Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. [europepmc]
- New Insights into the Pathogenesis of Giant Cell Arteritis: Mechanisms Involved in Maintaining Vascular Inflammation. [europepmc]
Related